Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Income | $13.2M | $42.9M | $29.0M | $6,303.0K | ($82.1M) | $26.0M | $164.0M | $317.8M | $421.6M | $292.5M | $538.8M | $699.0M | $1,061.7M | $814.9M | $805.4M | ($187.6M) | $593.6M | $555.9M | $979.7M | $1,184.9M |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, United Therapeutics Corporation's last 12-month Operating Income is $1,279.4M, based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, United Therapeutics Corporation's Operating Income growth was 16.3%. The average annual Operating Income growth rates for United Therapeutics Corporation have been 52.3% over the past three years, N/A over the past five years.
Over the last year, United Therapeutics Corporation's Operating Income growth was 16.3%, which is higher than industry growth of (0.1%). It indicates that United Therapeutics Corporation's Operating Income growth is Good.